Tiancheng (Germany) Pharmaceutical Holdings

Tiancheng (Germany) Pharmaceutical Holdings was a German healthcare holding company created to own a controlling stake in Biotest AG, a plasma-derived therapeutics and immunology company. The entity itself does not appear to have operated as an R&D-focused biotech or drug developer; rather, its primary role was as an acquisition and ownership vehicle for Biotest shares and related shareholder loan assets. In September 2021, Grifols agreed to acquire 100% of Tiancheng (Germany) Pharmaceutical Holdings from Tiancheng International Investment, and Grifols completed the transaction in April 2022 after regulatory approvals. Through that acquisition, Grifols obtained control of Biotest and expanded its plasma therapeutics footprint in Europe. For biotech landscape purposes, this entity is best classified as a healthcare holding company rather than an operating pharmaceutical developer.